The Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic Screens

PLoS Pathog. 2017 Feb 8;13(2):e1006180. doi: 10.1371/journal.ppat.1006180. eCollection 2017 Feb.

Abstract

In this study the 'Malaria Box' chemical library comprising 400 compounds with antiplasmodial activity was screened for compounds that perturb the internal pH of the malaria parasite, Plasmodium falciparum. Fifteen compounds induced an acidification of the parasite cytosol. Two of these did so by inhibiting the parasite's formate nitrite transporter (PfFNT), which mediates the H+-coupled efflux from the parasite of lactate generated by glycolysis. Both compounds were shown to inhibit lactate transport across the parasite plasma membrane, and the transport of lactate by PfFNT expressed in Xenopus laevis oocytes. PfFNT inhibition caused accumulation of lactate in parasitised erythrocytes, and swelling of both the parasite and parasitised erythrocyte. Long-term exposure of parasites to one of the inhibitors gave rise to resistant parasites with a mutant form of PfFNT that showed reduced inhibitor sensitivity. This study provides the first evidence that PfFNT is a druggable antimalarial target.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials / chemistry
  • Antimalarials / pharmacology*
  • Biological Transport / drug effects
  • Chromatography, Liquid
  • Drug Evaluation, Preclinical
  • Erythrocytes / parasitology*
  • Humans
  • Malaria, Falciparum / metabolism*
  • Malaria, Falciparum / parasitology
  • Mass Spectrometry
  • Monocarboxylic Acid Transporters / drug effects*
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / metabolism
  • Plasmodium falciparum / parasitology
  • Protozoan Proteins / metabolism
  • Xenopus laevis

Substances

  • Antimalarials
  • Monocarboxylic Acid Transporters
  • Protozoan Proteins

Grants and funding

Aspects of this work were supported by a Project Grant (1042272 to KK) from the Australian National Health and Medical Research Council (NHMRC). AML is the recipient of an Australian Research Council Discovery Early Career Researcher Award (DE160101035), REM was supported by a NHMRC Career Development Fellowship (1053082) and MJM is a NHMRC Principal Research Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.